A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours

Trial Profile

A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Acronyms ALIENOR
  • Most Recent Events

    • 14 Mar 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
    • 14 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Oct 2013 New source identified and integrated (European Clinical Trials Database record, EudraCT2012-002841-39).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top